{"id":"p-o-cefuroxime-500-mgx2-d-for-5-days","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Nausea"},{"rate":"1-3%","effect":"Headache"},{"rate":"1-3%","effect":"Vomiting"},{"rate":"1-2%","effect":"Hypersensitivity reactions"},{"rate":"1-2%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefuroxime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The oral formulation (P.O.) is well-absorbed and achieves therapeutic concentrations in most body tissues.","oneSentence":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:35.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial respiratory tract infections"},{"name":"Urinary tract infections"},{"name":"Skin and soft tissue infections"},{"name":"Lyme disease"},{"name":"Other susceptible bacterial infections"}]},"trialDetails":[{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":"Premature Rupture of Membrane","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"P.O cefuroxime 500 mgx2/d for 5 days","genericName":"P.O cefuroxime 500 mgx2/d for 5 days","companyName":"Western Galilee Hospital-Nahariya","companyId":"western-galilee-hospital-nahariya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and Lyme disease, Perioperative prophylaxis in surgical procedures.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}